Symbol | Exchange | Currency |
|---|
Drug discovery group e-therapeutics PLC (LON:ETX) has appointed Alison Gallafent as its head of intellectual property. A UK-chartered patent attorney and European patent attorney,...
Drug discovery group e-therapeutics PLC (LON:ETX) has appointed Alison Gallafent as its head of intellectual property. A UK-chartered patent attorney and European patent attorney,...
e-therapeutics plc (LON:ETX) has reached two key milestones in its collaboration with Galapagos NV, triggering two payments to the company. The two operational and success-based...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Sell | Sell | Buy |
| Technical Indicators | Strong Buy | Buy | Sell | Strong Sell | Strong Buy |
| Summary | Buy | Neutral | Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.29 | 4.35 | 4.10 | -0.010 | -0.23% | 3.55M | London | |||
| 5.174 | 5.174 | 5.174 | +0.6000 | +13.33% | 21.42M | London | |||
| 436.00 | 457.20 | 431.80 | -16.80 | -3.71% | 720.75K | London | |||
| 5.85 | 5.85 | 5.42 | -0.050 | -0.85% | 4.31M | London | |||
| 8.10 | 9.575 | 7.20 | +1.1000 | +15.71% | 229.73M | London | |||
| 3.94 | 4.28 | 3.50 | -0.56 | -12.44% | 592.70K | London | |||
| 396.00 | 407.50 | 390.00 | -9.00 | -2.23% | 253.63K | London | |||
| 220.44 | 227.06 | 220.40 | -4.56 | -2.03% | 376.31K | London | |||
| 3.228 | 3.228 | 3.228 | -0.100 | -2.98% | 1.77M | London | |||
| 40.84 | 40.84 | 40.84 | -2.66 | -6.11% | 4.16K | London | |||
| 218.00 | 221.00 | 217.00 | +1.00 | +0.46% | 653.54K | London | |||
| 43.58 | 43.58 | 43.58 | -1.50 | -3.26% | 157.65K | London | |||
| 64.10 | 66.18 | 63.56 | -0.36 | -0.56% | 11.16M | London | |||
| 78.14 | 82.00 | 73.50 | +4.64 | +6.31% | 359.00K | London | |||
| 8.22 | 8.91 | 8.01 | -0.58 | -6.59% | 2.75M | London |
e-Therapeutics Plc is a United Kingdom-based company, which provides computer-based drug discovery platform. The Company uses its Network-Driven Drug Discovery (NDD) platform to develop intellectual property protected and pre-clinical drug discovery programs. The Company utilizes its biological proficiency and computer-based platform to create and analyze network models of disease processes to identify patterns of proteins. NDD enables network analysis, data mining, machine learning, artificial intelligence and optimization to match drug-like small molecules to its networks based on their potential bioactivity.